| MDL | MFCD00865766 |
|---|---|
| Molecular Weight | 361.56 |
| Molecular Formula | C23H39NO2 |
| SMILES | O=C(C1=CC=C(C=C1)NCCCCCCCCCCCCCCCC)O |
Cetaben is a PPARα-independent peroxisome proliferator. Cetaben is a non-fibrate hypolipidemic drug and potently reduces the concentration of cholesterol and triglycerides [1] [2] .
Cetaben (10 µM; 24 hours) induces severe micromorphological and ultrastructural changes in HepG2 and MH1C1 cells. After treatment with 100 µM cetaben, cells contained several Golgi regions, most of them disintegrated into vesicles
[2]
.
Cetaben-treated (10 µM; 24 hours) cells were characterized by a striking heterogeneity of the peroxisomal population with the occurrence of dumbbell-shaped and cup-shaped peroxisomal profiles in MH1C1cells
[2]
.
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Cetaben reveales a significant rise in the activities of peroxisomal enzymes in both the liver and kidney at doses of 50-100 mg/kg body over 10 days, but the maximal effect is observed at 250 mg/kg
[1]
.
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
| Animal Model: | Male Wistar rats [1] |
| Dosage: | 10,25,50,100,250 and 500 mg/kg |
| Administration: | Gavage; 10 day |
| Result: | Revealed a significant rise in the activities of peroxisomal enzymes in both the liver and kidney at doses of 50-100 mg/kg body over 10 days, but the maximal effect was observed at 250 mg/kg. |
Solid
Room temperature in continental US; may vary elsewhere.
| Powder | -20°C | 3 years |
|---|---|---|
| In solvent | -80°C | 6 months |
| -20°C | 1 month |
DMSO : 10 mg/mL ( 27.66 mM ; ultrasonic and warming and heat to 60°C)
| Concentration Solvent Mass | 1 mg | 5 mg | 10 mg |
|---|
| 1 mM | 2.7658 mL | 13.8290 mL | 27.6579 mL |
| 5 mM | 0.5532 mL | 2.7658 mL | 5.5316 mL |
| 10 mM | 0.2766 mL | 1.3829 mL | 2.7658 mL |
Add each solvent one by one: 10% DMSO >> 90% corn oil
Solubility: ≥ 2.5 mg/mL (6.91 mM); Clear solution